FDA Warns Against Long-Term Azithromycin Use for Some
MONDAY, Aug. 13, 2018 -- The U.S. Food and Drug Administration is warning patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant not to take azithromycin, as long-term use of the antibiotic has been associated... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2018 Category: Pharmaceuticals Source Type: news

FDA: Don't Use Azithromycin for Lung Condition in Cancer Patients FDA: Don't Use Azithromycin for Lung Condition in Cancer Patients
The FDA warns of an increased risk for relapse of hematologic malignancy and for death when azithromycin is used to prevent bronchiolitis obliterans syndrome in hematopoietic stem cell transplant patients.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromax, Zmax) antibiotic after donor stem cell transplant
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2018 Category: Drugs & Pharmacology Source Type: news

Blood biomarker can help predict disease progression in patients with COPD
(Elsevier) Some patients with COPD demonstrate signs of accelerated aging. In a new study published in the journal CHEST ® researchers report that measuring blood telomeres, a marker of aging of cells, can be used to predict future risk of the disease worsening or death. Further, they have determined that the drug azithromycin may help patients with short telomeres, an indicator of more rapid biological aging, stave off negative clinical outcomes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2018 Category: International Medicine & Public Health Source Type: news

Azithromycin Cuts Pulmonary Exacerbation in CF With Early Pa
WEDNESDAY, June 27, 2018 -- For children with cystic fibrosis (CF) and early Pseudomonas aeruginosa (Pa) infection, the risk of pulmonary exacerbation is significantly reduced with the addition of azithromycin to tobramycin inhalation solution... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 27, 2018 Category: Pharmaceuticals Source Type: news

Pfizer announces extension of Zithromax ® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness
Pfizer Inc. will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company's 20-years of work to help eliminate the world's leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continue to provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD). (Source: World Pharma News)
Source: World Pharma News - June 14, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Macrolide antibiotics for bronchiectasis
This Cochrane Review of 15 RCTs found that long-term macrolide therapy may reduce the frequency of exacerbations and improve quality of life, although supporting evidence is derived mainly from studies of azithromycin, and predominantly among adults rather than children. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 1, 2018 Category: Consumer Health News Source Type: news

Randomised controlled trial tests azithromycin efficacy for asthma exacerbation
Wed, 05/16/2018 - 15:05News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - May 16, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Azithromycin: A Generic Antibiotic That Continues To Provide Surprising Life-Saving Benefits
Decades after it was synthesized in a lab in Groton, Connecticut, new uses of azithromycin are still being found to save lives. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 15, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Source Type: news

Trovan - Zithromax (Trovafloxacin and Azithromycin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 14, 2018 Category: Drugs & Pharmacology Source Type: news

Azithromycin (Azasite) Ophthalmic Solution 1% (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 9, 2018 Category: Drugs & Pharmacology Source Type: news

Zithromax (Azithromycin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2018 Category: Drugs & Pharmacology Source Type: news

Common antibiotic significantly reduces child deaths across Africa
Giving the antibiotic azithromycin twice a year to young children in sub-Saharan Africa reduced childhood deaths by 13.5%, a new study has shown. (Source: CNN.com - Health)
Source: CNN.com - Health - April 26, 2018 Category: Consumer Health News Source Type: news

Preventive use of common antibiotic reduces child mortality in sub-Saharan Africa
(University of California - San Francisco) Treating young children in Sub-Saharan Africa with azithromycin, a safe, inexpensive, and widely used antibiotic, significantly reduced deaths of children under five in a large randomized trial led by scientists at UC San Francisco. The finding could help speed progress toward the United Nations' goal of ending preventable child deaths by 2030. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 25, 2018 Category: Infectious Diseases Source Type: news

The World ’s First Case of Drug-Resistant ‘Super Gonorrhea’ Has Been Confirmed
This report is one more confirmation of our greatest fear: drug-resistant gonorrhea spreading around the globe,” David Harvey, executive director of the National Coalition of STD Directors, told CNN. The patient, who first sought medical care in early 2018, is being treated with an intravenous course of ertapenem, a powerful antibiotic typically used, at least in the U.S., for “serious infections in hospitalized patients,” according to the National Institutes of Health. The results of his next test are expected in mid-April. Gonorrhea is one of the world’s most common STIs, affecting 78 million peop...
Source: TIME: Health - March 30, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime public health Source Type: news